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Background. Primary breast angiosarcoma is a rare entity. Case. Initial diagnosis was a benign hemangioma at core biopsy. Wide
local excision was performed, with positive margins. Pathology after surgery reported a moderately diﬀerentiated angiosarcoma.
Tumor was ﬁnally treated using mastectomy and radiations. She developed a second angiosarcoma in contralateral breast, with
an initial diagnosis on core biopsy of an atypical vascular lesion and was again treated using mastectomy and radiations. She
developed bones and lung metastases. Conclusion. Primary breast angiosarcoma is a rare entity often diﬃcult to diagnose on core
biopsy, and a benign diﬀerential diagnosis is frequent. A highly vascular breast mass should always be considered malignant until
proven otherwise. Surgical treatment seems to be the best course of action. There is a lack of data proving eﬃcacy of adjuvant
chemotherapy and radiation therapy.
1.Introduction
Primary breast sarcomas are rare entities. These malignant
tumors originate from mesenchymental glandular breast
tissue and account for <1% of all breast cancer cases [1].
The more frequent histological subtypes encountered are
malignant ﬁbrous histiocytoma, ﬁbrosarcoma, liposarcoma,
and angiosarcoma. Most angiosarcomas are secondary to
radiotherapy treatments for breast cancer or to an arm
lymphoedema subsequent to a modiﬁed radical mastectomy.
Only about 20% of angiosarcomas are primary sarcomas.
The incidence of primary breast angiosarcoma is about 17
new cases per million women. Most literature about these
cases is case reports, and this tumors’ natural history is thus
only partially understood and its treatment lacks uniformity.
The present case report presents a new case and reviews the
existing literature in the aim of achieving a better deﬁnition
ofthetreatmentofthiscancerandavoidingthecommontrap
of a benign diﬀerential diagnosis.
2.CaseReport
A 28-year-old patient, mother of two children, presented in
October 2003 for a painless slowly growing mass in her left
breast. She had no personal or family history of breast or
ovarian cancer. Except for the suspect mass, she was in good
health.
Since her last pregnancy in 2000, her left breast progres-
sively enlarged. However, in the last 3 months, the enlarge-
ment rate increased, to the expense of the superior and
median quadrants. She had no other breast symptom. Mam-
mography showed a nonspeciﬁc and diﬀuse density area of
about 7cm and septa measuring up to 10cm. There was no
mammographicmicrocalciﬁcationordistortionnoranyskin
anomaly.
At physical examination, there was an important asym-
metry at the expense of the left breast upper area. Repeated
sonography showed a diﬀuse and ill delimited hypere-
chogenicinﬁltrationinthesuperiorportionoftheleftbreast,2 Case Reports in Oncological Medicine
Figure 1: Hematoxylin and eosin stain on an ill-diﬀerentiated part
of the left breast’s angiosarcoma (200x).
spanning 16cm in transversal and 10cm in cephalocaudal
planes. There was no inﬁltration of the pectoral muscle. A
core needle biopsy (CNB) was performed and demonstrated
the presence of a nonatypical vascular lesion interpreted as a
benign capillary hemangioma.
WedecidedtotrytoremovethewholemassinNovember
2003. During surgery, in the lower portion of the left
breast, margins were much ill deﬁned and the lesion seemed
more aggressive than a simple hemangioma. A sample
of the tumor was sent to the pathology laboratory for
intraoperative consultation, and the frozen section diagnosis
was one of an “atypical vascular tumor, ﬁnal diagnosis of
benign or malignant tumor deferred on permanent section”.
Hemostasiswasalsodiﬃculttoachieve,andsurgicaldecision
was to perform a wide local excision.
Finalpathologydiagnosiswasamoderatelydiﬀerentiated
angiosarcoma (grade II/III), measuring 12cm on its larger
axis. However, the tumor could be larger since all margins
were positive. There was no skin invasion. Both estrogen
and progesterone receptors were negative. Postsurgery blood
screenings and axial tomography were all normal. We
completed surgical treatment with a total left mastectomy
extendedtotheskininDecember2003.ATRAMreconstruc-
tion was performed in order to replace removed skin and to
close the wound.
Pathology on total left mastectomy conﬁrmed a residual
angiosarcoma grade II/III. Figure 1 shows an ill-diﬀerentia-
ted part of the tumor (hematoxylin and eosin stain, 200x).
Figure 2 shows tumor positivity for CD31 (immunohisto-
chemistry, 200x). All margins were ﬁnally negative. After
tumor board discussion, no adjuvant chemotherapy was
administered. She received radiation therapy to the left chest
wall (60Gy in 30 fractions) since local recurrence of this type
of tumor was very likely. She received all her treatments, and
she had a followup, including physical examination and CT
scan, on a 6 months basis. In November 2004, there was
no recurrence in the reconstructed left breast, and the right
breastwasnormal.Acohesivegelimplantwasinstalledinthe
left breast in April 2005.
Figure 2: CD31 immunohistochemistry in left breast’s angiosar-
coma (200x).
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Figure 3: Magnetic resonance imagery showing the left breast
implant and the highly vascular mass encompassing most of the
right breast.
On December 2005, a suspect 2cm mass was discovered
in the right breast. Fine needle aspiration (FNA) was per-
formed at her local medical centre and was negative. Further
investigations using mammography, sonography, and CNB
were performed and were reported as benign. Hypere-
chogenic area in lower part of the right breast was consistent
with an hematoma. She was referred at our center in April
2006.Lesionwasthen6×8cm,wellﬁxedtocutaneoustissue,
but otherwise mobile. The hyperechogenic area was still
present,withmuchilldeﬁnedborders.Asonography-guided
NCB was performed, and material retrieved contained much
blood. Pathology diagnosis was an atypical vascular lesion,
and a well-diﬀerentiated angiosarcoma could not be ruled
out. The magnetic resonance imagery (MRI) (Figure 3)
showed the implant in the left breast and showed the mass
in the right breast, encompassing most of the breast. Since it
wasimpossibletoruleoutthepossibilitythatitwasaportion
of a well-diﬀerentiated angiosarcoma, a total mastectomy
with immediate reconstruction of the right breast was per-
formed in April 2006. Pathology reported a well- to poorly-
diﬀerentiatedangiosarcoma(gradeI/IIItoIII/III)measuring
8cmonitslongeraxis.Tumorwasilldelimitedwithinvasion
of adipose tissue and mammary parenchyma. At the centerCase Reports in Oncological Medicine 3
of this mass, necrosis and blood lakes were found. There
was dermal invasion, but epidermis was intact. Estrogen
and progesterone receptors were negative. Endothelial cells
bordering blood vessels were positive for CD34, CD31,
factor VIII, and vimentin and were negative to keratin 8-
18, concordant with a vascular origin. The 2006 tumor was
compared to the one from 2003 and was very similar in their
well-diﬀerentiated parts. One margin was positive and had
to be removed in May 2006. A total radiation dose of 60Gy
was administrated in 30 fractions to the right chest wall. In
November 2006, a PET scan showed some inﬁltrates in the
right lung, suggestive of postirradiation changes.
In December 2008, a lytic lesion was found in the
right humerus encompassing the whole cortex and the
posterior portion of the humeral head. There was also an
osteolytic lesion in the D8 vertebrae. The humeral lesion
was metabolically highly active. The whole humeral head
was removed and replaced by a prosthesis in January 2009.
Pathology reported an angiosarcoma without invasion. The
area was irradiated with a total dose of 20Gy in 5 fractions.
The vertebral lesion was treated using radiation (40Gy in 15
fractions).
In July 2009, multiple bilateral lung metastases were fou-
nd, and a progression was observed in the D8 lesion. Patient
received palliative care.
3. Discussion
Breast angiosarcoma can be observed as a primary neoplasm
or, more commonly, secondary to breast-conserving surgery
combined to radiation therapy. In the present paper, in
accordancetothecasereported,primaryangiosarcomasonly
will be discussed. Primary breast sarcomas and angiosarco-
mas represent, respectively, less than 1% and 0.04% of all
breast cancers [1]. Breast angiosarcoma is more frequent
i ny o u n gw o m e n( 2 0t o5 0y e a r s )w i t hn op r e v i o u sc a n c e r
history or other known risk factors [2, 3]. Between 6
and 12% of primary breast angiosarcomas are diagnosed
during pregnancy or shortly after, suggesting hormones
involvement. However, cases reported to display positive
estrogen receptors are so rare, that it is presently impossible
to establish a link between angiosarcomas and hormonal
dependency [4, 5]. In the case reported here, estrogen and
p r o g e s t e r o n er e c e p t o r sw e r eb o t hn e g a t i v e s .
In most published cases, breast angiosarcoma presents as
a palpable mass, without pain and with a fast growing rate
[6, 7]. Large or superﬁcial tumors often present purplish,
ecchymosis-like skin coloration [7]. In most cases, absence
of pathognomonic characteristics speciﬁc to angiosarcomas
will result in a wrong or delayed diagnosis [6, 8]. Radiologic
characteristics may help to establish right diagnosis, but,
most often, as in the present case, mammography is unspe-
ciﬁc and heterogeneous. Sonography and MRI are useful in
characterizing breast lesions, but again there is no distinctive
features to angiosarcomas [6, 7]. MRI shows a low signal
on T1-weighted images and a high signal on T2-weighted
images [9, 10]. Positron emission tomography (PET) scan
using 18F-FDG has shown an intense FDG accumulation in
angiosarcomas and might be useful [9, 11].
In most cases, tumor size at diagnosis is larger than 4cm
[4]. As most soft-tissue sarcoma in most anatomical sites
and of most histological subtype, angiosarcomas larger than
5cm are associated to a shorter disease-free survival than
angiosarcomas smaller than 5cm. Indeed, tumors smaller
than 5cm are usually associated to a better prognosis,
even in the presence of worsening factors. With small
tumors, recurrence is usually local and distant metastases are
infrequent. However, tumors larger than 5cm are associated
to distant metastases, independently of local recurrence
[1, 12]. There is a need for a close follow-up, including
computed tomography scans at 6-month intervals.
Sondenaa et al. conducted a survey of metastatic sites
of all reported primary breast angiosarcoma. They con-
cluded that the liver was the more frequent metastatic
s i t e ,f o l l o w e db yl u n g ,l y m p hn o d e s ,b o n e s ,b o n em a r -
row and, less frequently, ovary, kidney, omentum, adrenal
gland, stomach, pancreas, peritoneum, esophagus, and skin
[13]. Breast angiosarcomas are stratiﬁed according to three
grades. Well-diﬀerentiated tumors (grade I) are composed of
anastomosing vascular channels that surround breast ducts
and inﬁltrate the adipose tissue. Blood vessels are lined
by a single layer of endothelial cells with hyperchromatic
nuclei showing little mitosis. No endothelial tufting is seen.
Well-diﬀerentiated breast angiosarcomas are associated to a
longer recurrence-free survival and to fewer distant metas-
tases. Moderately diﬀerentiated angiosarcomas (grade II) are
largely like well-diﬀerentiated tumors but show small foci of
solid proliferation of spindle-shaped cells and more mitotic
ﬁgures. Poorly-diﬀerentiated angiosarcomas present more
solid and atypical cell proliferation and often show necrotic
area and blood lakes. Grade III tumors are associated to
decreased ﬁve-year survival rate and to increased metastases
rate [4].
Diagnosis prior to surgery, either by FNA or NCB, is
at best diﬃcult [4]. Chen et al. reported a percutaneous
biopsy false-negative rate of 37% [14]. Diﬀerential diagnosis
of this rare tumor include: benign hemangioma, cystosar-
coma phyllodes, stromal sarcoma, metaplastic carcinoma,
ﬁbrosarcoma, liposarcoma, squamous cell carcinoma with
sarcomatoid features, myoepithelioma, ﬁbromatosis, and
reactive spindle cell proliferative lesion [4, 15]. Large-core
macrobiopsies might be useful to improve diagnosis prior to
surgery since a larger sample is taken [16]. However, in the
present case, the mass was so importantly hemorrhagic that
a macrobiopsy would have been very diﬃcult to perform.
Surgical resection and microscopic examination of suﬃcient
sampling of the tumor are often necessary to render a ﬁnal
diagnosis. Immunohistochemical examination (factor VIII
and CD31 positivity) will conﬁrm the vascular nature of the
tumor [4, 7].
It is now well recognized that complete surgical excision
of breast angiosarcoma is the best course of action and that
total mastectomy is the best option [17]. Since hematogen
dissemination is more than likely, axillary node dissection is
not indicated [6, 15, 17, 18]. Also, many authors’ opinion is
that breast conservative surgery is not acceptable [6, 14, 19,
20], since the recurrence rate of wide local excision is 23%
versus 8% for total mastectomy [21]. However, according to4 Case Reports in Oncological Medicine
some authors, wide local excision would be indicated if the
tumorissmallerthan5cm[15,22].Thereisnotenoughdata
in the current literature to support either course of action.
Also, since sarcomas are very active and invasive lesions,
negative surgical margins are diﬃcult to achieve at ﬁrst
surgery. In many reported cases, it is often said that surgical
margins are positive after breast conservative surgery and
that total mastectomy must then be performed [6, 14, 15],
as in the present case.
It is generally recognized that breast angiosarcomas have
a bad prognosis. However, prognosis depends upon tumor
grade (most important factor), tumor size at diagnosis, and
margin status at surgery [6]. Generally, 33% of patients with
breast angiosarcoma, all grades together, are disease-free 5
years after initial diagnosis. Most of patients with a grade
I/III tumor are alive after 15 years. Grade III/III tumors are
the most aggressive, and the median disease-free survival is
about 15 months.
Chemotherapy and radiation therapy may be used
as adjuvant treatment. However, the role of adjuvant
chemotherapy is ill deﬁned, because of the rarity of primary
breast angiosarcoma and of the lack of prospective studies
[6, 15, 22]. Most primary breast angiosarcomas are treated
the same way as breast angiosarcoma secondary to radiation
therapy. In most reported cases with use of chemotherapy,
authors prescribed cyclophosphamide, anthracycline, or an
alkylating agents combined to a pyrimidine analog [6].
Paclitaxel have been shown to produce excellent responses
in a number of studies in a variety of anatomic sites [23–
28]. New agents against angiogenesis, such as bevacizumab
[29–33] or rapamycin [34], might also be useful against this
tumor. Study by Sher et al. shows a 48% overall response rate
to chemotherapy, especially using anthracycline-ifosfamide
or gemcitabine-taxane therapies [5]. Chemotherapy might
have a greater eﬃcacy in higher grade tumors [15]. Con-
cerning radiation therapy for breast angiosarcoma, data are
insuﬃcient and there is no clue about its eﬃcacy to improve
disease-free survival or to prevent metastatic spread. Also, no
recovery was ever reported with the use of radiation therapy
alone, and angiosarcomas seem to have some resistance to
radiations [6]. Since the high likelihood of locoregional
recurrence, radiation therapy might be indicated even after
a total mastectomy [35]. Indeed, in the case reported here,
the patient received radiation therapy to her left breast and
she did not develop a recurrence to this breast. As with
any cancer type, margins status is a major risk factor for
recurrence [17].Itiswhysomeauthorsrecommendadjuvant
radiation therapy when surgical margins are positive [36,
37] or when surgical margins are less than 2cm [38].
Radiation therapy may be used for palliative treatment of
pain secondary to bone metastasis [6]. As future therapy,
targeted treatment against angiogenesis might be added to
the therapeutic arsenal against angiosarcoma.
4. Conclusion
A large and metabolically active vascular mass in the breast
should always be considered at ﬁrst sight to be an angiosar-
coma, until proven otherwise. Even if these tumors have
a bad prognosis, surgical treatment using total mastectomy
are preferred; wide local excision may be selected depending
on tumor size. Early and precise diagnosis is an important
prognostic factor. A close followup within the same centre
is capital. Primary breast angiosarcoma is a rare entity,
literature contains few data concerning adjuvant treatment,
and there is no generally agreed course of action. Hormonal
treatment doesn’t seem to be appropriate since these tumors
usually do not express estrogen receptors. Randomized,
controlled, prospective studies should be conducted to have
a better understanding of the role of adjuvant treatment in
breast angiosarcoma. However, rarity of the disease might
be a serious problem to these studies. It is thus important
to report these cases and to present treatments and patient’s
evolution.
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